Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Acquired Immunodeficiency Syndrome (AIDS) Market Set To Climb From $35.53 Billion In 2026 To $43.28 Billion By 2030
The market for acquired immunodeficiency syndrome (aids) has shown significant growth in recent years. It is anticipated to increase from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. Factors contributing to its historical expansion include the high global prevalence of HIV infections, expanded awareness and screening initiatives, government-backed HIV treatment programs, the introduction of first-generation antiretroviral drugs, and a rising occurrence of opportunistic infections.
The acquired immunodeficiency syndrome (aids) market size is projected to experience substantial growth in the upcoming years. It is forecast to reach $43.28 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This anticipated expansion can be attributed to the advancement of next-generation antiretroviral therapies, the broadening scope of PrEP and PEP initiatives, increased research in HIV vaccines, the adoption of digital health monitoring solutions, and a rise in public-private collaborations for HIV management. Key trends identified for the forecast period include the increasing uptake of antiretroviral therapy (ART), a growing reliance on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the expansion of HIV diagnostic and surveillance programs, a heightened emphasis on HIV vaccine research and development, and the integration of hospital and retail pharmacy services.
Get A Free Sample Report With In-Depth Market Insights:
Acquired Immunodeficiency Syndrome (AIDS) Market Growth Momentum: What Factors Are Shaping Demand?
A rise in HIV infection rates is projected to stimulate the expansion of the acquired immunodeficiency syndrome (AIDS) market in the coming years. HIV infections denote a state resulting from the human immunodeficiency virus (HIV), which targets the immune system, thereby compromising the body’s defenses against illnesses and infections. The escalating incidence of HIV infections stems from factors such as unprotected sexual contact with an infected individual, the sharing of needles or syringes, exposure to contaminated blood products, engaging with multiple sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections. Management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infection through fostering early diagnosis, broadening availability of potent antiretroviral therapies, improving prevention approaches, and reinforcing healthcare infrastructure, all of which aid in better containment of the virus’s propagation. For example, in November 2024, data released by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, indicated that 112,883 HIV diagnoses were reported in 2023 across 47 of 53 countries in the region, including 24,731 cases in the European Union/European Economic Area (EU/EEA). The overall crude rate of HIV diagnoses reached 12.7 per 100,000 population, showing a 2.4% increase from the 12.4 per 100,000 rate noted in 2022. Consequently, the rise in HIV infections is serving as a primary impetus for the acquired immunodeficiency syndrome (AIDS) market.
Acquired Immunodeficiency Syndrome (AIDS) Market Breakdown By Product Type And Application
The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
Acquired Immunodeficiency Syndrome (AIDS) Market Trends Redefining Industry Growth
Leading companies within the acquired immunodeficiency syndrome (AIDS) market are concentrating on developing innovative therapies, such as long-acting injectables, which offer enhanced patient compliance, reduce the frequency of administration, and provide a more convenient option compared to daily oral antiretroviral treatments. These long-acting injectables are medications delivered by injection, designed to release their active components gradually over an extended period, thereby requiring less frequent dosing than traditional oral medications. For example, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that it had received approval from the European Commission for its long-acting injectable treatment, Vocabria (cabotegravir) combined with Rekambys (rilpivirine). This therapy is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically either every one or two months, depending on the specific treatment plan. The prolonged action of these injections has the potential to improve adherence rates among adolescents who face difficulties with daily pill regimens.
Acquired Immunodeficiency Syndrome (AIDS) Market Company Landscape And Competitive Strategy
Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
View The Full Acquired Immunodeficiency Syndrome (AIDS) Market Report:
Acquired Immunodeficiency Syndrome (AIDS) Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.